Search research articles
Contact Us
Filters
Showing results (51-60 of 90) with videos related to
Page
of 9
Sort By:
Journal of Clinical Medicine
|
October 13, 2021
PD-L1 Inhibitors as Monotherapy for the First-Line Treatment of Non-Small-Cell Lung Cancer in PD-L1 Positive Patients: A Safety Data Network Meta-Analysis
María Rosario García Campelo, Edurne Arriola, Begoña Campos Balea, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 24, 2025
Phase I Dose-Escalation Results for the Delta-Like Ligand 3/CD3 IgG-Like T-Cell Engager Obrixtamig (BI 764532) in Patients With Delta-Like Ligand 3+ Small Cell Lung Cancer or Neuroendocrine Carcinomas
Martin Wermke, Valentina Gambardella, Yasutoshi Kuboki, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 22, 2026
Patient-reported outcomes from the LAURA study: osimertinib in patients with unresectable stage III EGFR-mutated non-small cell lung cancer after definitive chemoradiotherapy
Edurne Arriola, Ignacio Casarini, Mustafa Özgüroğlu, et al.
Lung Cancer (Amsterdam, Netherlands)
|
June 15, 2026
Osimertinib after definitive CRT in unresectable stage III EGFR-mutated NSCLC: safety outcomes from the phase III LAURA study
Terufumi Kato, Xiaorong Dong, Toshiaki Takahashi, et al.
Frontiers in Immunology
|
June 29, 2026
Peripheral immune cell subsets as potential predictors of benefit from immune checkpoint blockade therapy in small cell lung cancer
Miguel A Galindo-Campos, Max Hardy-Werbin, Joan Gibert, et al.
Oncoimmunology
|
May 10, 2019
Serum cytokine levels as predictive biomarkers of benefit from ipilimumab in small cell lung cancer
Max Hardy-Werbin, Pedro Rocha, Oriol Arpi, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology
|
March 12, 2008
Genomic analysis of the HER2/TOP2A amplicon in breast cancer and breast cancer cell lines
Edurne Arriola, Caterina Marchio, David S P Tan, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
July 29, 2016
An Open-Label, Multicenter, Randomized, Phase II Study of Cisplatin and Pemetrexed With or Without Cixutumumab (IMC-A12) as a First-Line Therapy in Patients With Advanced Nonsquamous Non-Small Cell Lung Cancer
Silvia Novello, Giorgio Scagliotti, Gilberto de Castro, et al.
JCO Precision Oncology
|
March 2, 2023
Cost-Effectiveness of Next-Generation Sequencing Versus Single-Gene Testing for the Molecular Diagnosis of Patients With Metastatic Non-Small-Cell Lung Cancer From the Perspective of Spanish Reference Centers
Edurne Arriola, Reyes Bernabé, Rosario García Campelo, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
November 26, 2010
Increased ALK gene copy number and amplification are frequent in non-small cell lung cancer
Marta Salido, Lara Pijuan, Luz Martínez-Avilés, et al.
Page
of 9
Search research articles
Search
Showing results (51-60 of 90) with videos related to
Sort By:
Page
of 9
Journal of Clinical Medicine
|
October 13, 2021
PD-L1 Inhibitors as Monotherapy for the First-Line Treatment of Non-Small-Cell Lung Cancer in PD-L1 Positive Patients: A Safety Data Network Meta-Analysis
María Rosario García Campelo, Edurne Arriola, Begoña Campos Balea, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 24, 2025
Phase I Dose-Escalation Results for the Delta-Like Ligand 3/CD3 IgG-Like T-Cell Engager Obrixtamig (BI 764532) in Patients With Delta-Like Ligand 3+ Small Cell Lung Cancer or Neuroendocrine Carcinomas
Martin Wermke, Valentina Gambardella, Yasutoshi Kuboki, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 22, 2026
Patient-reported outcomes from the LAURA study: osimertinib in patients with unresectable stage III EGFR-mutated non-small cell lung cancer after definitive chemoradiotherapy
Edurne Arriola, Ignacio Casarini, Mustafa Özgüroğlu, et al.
Lung Cancer (Amsterdam, Netherlands)
|
June 15, 2026
Osimertinib after definitive CRT in unresectable stage III EGFR-mutated NSCLC: safety outcomes from the phase III LAURA study
Terufumi Kato, Xiaorong Dong, Toshiaki Takahashi, et al.
Frontiers in Immunology
|
June 29, 2026
Peripheral immune cell subsets as potential predictors of benefit from immune checkpoint blockade therapy in small cell lung cancer
Miguel A Galindo-Campos, Max Hardy-Werbin, Joan Gibert, et al.
Oncoimmunology
|
May 10, 2019
Serum cytokine levels as predictive biomarkers of benefit from ipilimumab in small cell lung cancer
Max Hardy-Werbin, Pedro Rocha, Oriol Arpi, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology
|
March 12, 2008
Genomic analysis of the HER2/TOP2A amplicon in breast cancer and breast cancer cell lines
Edurne Arriola, Caterina Marchio, David S P Tan, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
July 29, 2016
An Open-Label, Multicenter, Randomized, Phase II Study of Cisplatin and Pemetrexed With or Without Cixutumumab (IMC-A12) as a First-Line Therapy in Patients With Advanced Nonsquamous Non-Small Cell Lung Cancer
Silvia Novello, Giorgio Scagliotti, Gilberto de Castro, et al.
JCO Precision Oncology
|
March 2, 2023
Cost-Effectiveness of Next-Generation Sequencing Versus Single-Gene Testing for the Molecular Diagnosis of Patients With Metastatic Non-Small-Cell Lung Cancer From the Perspective of Spanish Reference Centers
Edurne Arriola, Reyes Bernabé, Rosario García Campelo, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
November 26, 2010
Increased ALK gene copy number and amplification are frequent in non-small cell lung cancer
Marta Salido, Lara Pijuan, Luz Martínez-Avilés, et al.
Page
of 9